Literature DB >> 26423143

[Use in France of Baclofen for Alcohol Dependence from 2007 to 2013: Cohort Study Based on the Databases SNIIRAM and PMSI].

Christophe Chaignot1, Alain Weill1, Philippe Ricordeau1, François Alla2.   

Abstract

AIM: To quantify and describe the population starting treatment with baclofen for alcohol dependence during the period 2007-2013 in France.
METHODS: The French national health insurance (système national d'information inter-régimes de l'Assurance maladie [SNIIRAM]) and French hospital discharge (programme de médicalisation des systèmes d'information [PMSI]) databases were used to identify the population starting treatment with baclofen, determine the algorithm of baclofen use, define patient characteristics and their treatment.
RESULTS: About 200,000 subjects initiated baclofen therapy between 2007 and 2013, for alcohol dependence in 52.0% of cases. In 2013, this population was predominantly male (62.3%), with a mean age of 50.1 years, the first prescriber was a general practitioner in 58.9% of cases, they continued their treatment 6 months after their initiation in 48.8% of cases and one half of these subjects consumed at least 57.0 mg of baclofen daily.
CONCLUSIONS: The use of baclofen for alcohol dependence increased considerably since 2008, with more than 34,000 new users and more than 9,000 general practitioners as first prescribers in 2013.
© 2015 Société Française de Pharmacologie et de Thérapeutique.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26423143     DOI: 10.2515/therapie/2015027

Source DB:  PubMed          Journal:  Therapie        ISSN: 0040-5957            Impact factor:   2.070


  9 in total

1.  Proactive Regional Pharmacovigilance System Versus National Spontaneous Reporting for Collecting Safety Data on Concerning Off-Label Prescribing Practices: An Example with Baclofen and Alcohol Dependence in France.

Authors:  Marine Auffret; Julien Labreuche; Alain Duhamel; Sylvie Deheul; Olivier Cottencin; Régis Bordet; Sophie Gautier; Benjamin Rolland
Journal:  Drug Saf       Date:  2017-03       Impact factor: 5.606

Review 2.  GABAB Receptors and Alcohol Use Disorders: Clinical Studies.

Authors:  Warren B Logge; Kirsten C Morley; Paul S Haber
Journal:  Curr Top Behav Neurosci       Date:  2022

3.  Drug-drug interactions with imatinib: An observational study.

Authors:  Isabelle Récoché; Vanessa Rousseau; Robert Bourrel; Maryse Lapeyre-Mestre; Leila Chebane; Fabien Despas; Jean-Louis Montastruc; Emmanuelle Bondon-Guitton
Journal:  Medicine (Baltimore)       Date:  2016-10       Impact factor: 1.889

4.  Baclofen Response in Alcohol Dependent Patients Concurrently Receiving Antidepressants: Secondary Analysis From the BacALD Study.

Authors:  Sovandara Heng; Nazila Jamshidi; Andrew Baillie; Eva Louie; Glenys Dore; Nghi Phung; Paul S Haber; Kirsten C Morley
Journal:  Front Psychiatry       Date:  2018-11-19       Impact factor: 4.157

5.  Neurometabolite Levels in Alcohol Use Disorder Patients During Baclofen Treatment and Prediction of Relapse to Heavy Drinking.

Authors:  Kirsten C Morley; Jim Lagopoulos; Warren Logge; Kate Chitty; Andrew Baillie; Paul S Haber
Journal:  Front Psychiatry       Date:  2018-09-04       Impact factor: 4.157

6.  R(+)-Baclofen, but Not S(-)-Baclofen, Alters Alcohol Self-Administration in Alcohol-Preferring Rats.

Authors:  Irene Lorrai; Paola Maccioni; Gian Luigi Gessa; Giancarlo Colombo
Journal:  Front Psychiatry       Date:  2016-04-18       Impact factor: 4.157

Review 7.  Safety Challenges of Using High Dose Baclofen for Alcohol Use Disorder: A Focused Review.

Authors:  Benjamin Rolland; Nicolas Simon; Nicolas Franchitto
Journal:  Front Psychiatry       Date:  2018-08-22       Impact factor: 4.157

8.  Can baclofen change alcohol-related cognitive biases and what is the role of anxiety herein?

Authors:  Esther M Beraha; Elske Salemink; Erwin Krediet; Reinout W Wiers
Journal:  J Psychopharmacol       Date:  2018-06-13       Impact factor: 4.153

9.  Risk of hospitalisation and death related to baclofen for alcohol use disorders: Comparison with nalmefene, acamprosate, and naltrexone in a cohort study of 165 334 patients between 2009 and 2015 in France.

Authors:  Christophe Chaignot; Mahmoud Zureik; Grégoire Rey; Rosemary Dray-Spira; Joël Coste; Alain Weill
Journal:  Pharmacoepidemiol Drug Saf       Date:  2018-09-25       Impact factor: 2.890

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.